Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Daniel R Selvig"'
Autor:
Elvira Mennillo, Yang Joon Kim, Gyehyun Lee, Iulia Rusu, Ravi K. Patel, Leah C. Dorman, Emily Flynn, Stephanie Li, Jared L. Bain, Christopher Andersen, Arjun Rao, Stanley Tamaki, Jessica Tsui, Alan Shen, Madison L. Lotstein, Maha Rahim, Mohammad Naser, Faviola Bernard-Vazquez, Walter Eckalbar, Soo-jin Cho, Kendall Beck, Najwa El-Nachef, Sara Lewin, Daniel R. Selvig, Jonathan P. Terdiman, Uma Mahadevan, David Y. Oh, Gabriela K. Fragiadakis, Angela Pisco, Alexis J. Combes, Michael G. Kattah
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Ulcerative colitis (UC) is driven by immune and stromal subsets, culminating in epithelial injury. Vedolizumab (VDZ) is an anti-integrin antibody that is effective for treating UC. VDZ is known to inhibit lymphocyte trafficking to the intest
Externí odkaz:
https://doaj.org/article/0ea20593138a4ffda5f1bf392dc9a45e
Autor:
Elvira Mennillo, Yang Joon Kim, Iulia Rusu, Gyehyun Lee, Leah C. Dorman, Faviola Bernard-Vazquez, Jared L. Bain, Ravi Patel, Christopher Andersen, Arjun Rao, Stanley Tamaki, Jessica Tsui, Alan Shen, Mohammad Naser, Walter Eckalbar, Soo-jin Cho, Kendall Beck, Najwa El-Nachef, Sara Lewin, Daniel R Selvig, Jonathan P Terdiman, Uma Mahadevan, David Y. Oh, Gabriela K. Fragiadakis, Angela Pisco, Alexis J. Combes, Michael G. Kattah
Publikováno v:
bioRxiv
Ulcerative colitis (UC) is an inflammatory intestinal disorder driven by mucosal immune and stromal subsets, culminating in epithelial injury. Vedolizumab (VDZ) is an anti-integrin monoclonal antibody that is effective for treating UC. VDZ is thought
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e27186b79baedb645bd0b8ac9f32482
https://europepmc.org/articles/PMC9882264/
https://europepmc.org/articles/PMC9882264/